<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063217</url>
  </required_header>
  <id_info>
    <org_study_id>201304030</org_study_id>
    <secondary_id>P50AG005681-30</secondary_id>
    <nct_id>NCT02063217</nct_id>
  </id_info>
  <brief_title>Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction</brief_title>
  <official_title>Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to change the concentration of amyloid-beta in human
      cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to investigate whether or not increasing or decreasing
      duration of sleep over one night will change the concentration of amyloid-beta in cerebral
      spinal fluid (CSF).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Increase From Mean Baseline (07:00 to 19:00) of Cerebrospinal Fluid (CSF) Amyloid Beta During Sleep Induction and Sleep Deprivation Between 01:00 and 11:00 From Baseline</measure>
    <time_frame>Baseline = 07:00 to 19:00; Intervention period = 01:00 to 11:00</time_frame>
    <description>Overnight (01:00 to 11:00) differences in CSF amyloid beta from baseline (07:00 to 19:00) between 1) sleep-deprived and control participants and 2) sleep-induced and control participants.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Amyloid-beta</condition>
  <arm_group>
    <arm_group_label>Sleep Induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 grams of sodium oxybate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate</intervention_name>
    <description>Sodium oxybate h.s.</description>
    <arm_group_label>Sleep Induction</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep deprivation</intervention_name>
    <description>36hr sleep deprivation</description>
    <arm_group_label>Sleep Deprivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cognitively normal or CDR 0

          -  negative for amyloid deposition by PET Pittsburgh Compound-B (PIB) imaging or CSF
             amyloid-beta-42 concentration

          -  Age 18-60

          -  Average reported sleep time 6-10hrs

        Exclusion Criteria:

          -  diagnosis of a sleep disorder such as sleep apnea, narcolepsy, or restless leg
             syndrome

          -  positive ambulatory sleep study for obstructive sleep apnea (AHI &gt; 5 respiratory
             events per hour) that will be performed as part of initial screening prior to
             enrollment

          -  Clinical Dementia Rating (CDR) &gt; 0

          -  tremor or other neurologic injury in the non-dominant upper extremity (such as stroke
             or tremor) that would prevent the use of actigraphy

          -  current sleep walking or other sleep parasomnia

          -  diagnosis and treatment of stroke, myocardial infarction or heart attack,

          -  coronary artery disease, atrial fibrillation, or congestive heart failure

          -  diagnosis and treatment of asthma or Chronic Obstructive Pulmonary Disease (COPD)

          -  diagnosis and treatment of bipolar disorder, major depression, or Schizophrenia

          -  current urinary or fecal incontinence

          -  currently on a low salt diet

          -  diagnosis and treatment of a neurologic disorder such as Parkinson's disease,
             epilepsy, multiple sclerosis

          -  currently taking any blood thinner medications such as warfarin, Plavix, or Aspirin

          -  kidney disease resulting in renal impairment

          -  liver disease resulting in hepatic dysfunction

          -  Pregnancy

          -  currently taking sedating medications such as benzodiazepines

          -  alcohol use at bedtime

          -  tobacco use

          -  BMI &gt;40

          -  contraindication to lumbar puncture

          -  diabetes

          -  sleep schedule outside the range of bedtime: 8pm-12am and waketime 4am-8am

          -  self reported difficulty sleeping in an unfamiliar environment

          -  use of sedative-hypnotic medications

          -  inability to get in and out of bed

          -  history or presence of any clinically significant medical condition, behavioral or
             psychiatric disorder, or surgical history based on medical record or patient report

          -  history of drug abuse within the past 6 months

          -  positive score on 2 or more categories on the Berlin questionnaire

          -  participation in another investigational medicinal product or investigational device
             within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Lucey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>March 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2018</results_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sleep Induction</title>
          <description>6.5-7.5 grams of sodium oxybate
Sodium Oxybate: Sodium oxybate h.s.</description>
        </group>
        <group group_id="P2">
          <title>Sleep Deprivation</title>
          <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods
Sleep deprivation: 36hr sleep deprivation</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sleep Induction</title>
          <description>6.5-7.5 grams of sodium oxybate
Sodium Oxybate: Sodium oxybate h.s.</description>
        </group>
        <group group_id="B2">
          <title>Sleep Deprivation</title>
          <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods
Sleep deprivation: 36hr sleep deprivation</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" lower_limit="20.8" upper_limit="58.3"/>
                    <measurement group_id="B2" value="42.0" lower_limit="18.8" upper_limit="58.6"/>
                    <measurement group_id="B3" value="42.7" lower_limit="25" upper_limit="57.2"/>
                    <measurement group_id="B4" value="43.3" lower_limit="18.8" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Increase From Mean Baseline (07:00 to 19:00) of Cerebrospinal Fluid (CSF) Amyloid Beta During Sleep Induction and Sleep Deprivation Between 01:00 and 11:00 From Baseline</title>
        <description>Overnight (01:00 to 11:00) differences in CSF amyloid beta from baseline (07:00 to 19:00) between 1) sleep-deprived and control participants and 2) sleep-induced and control participants.</description>
        <time_frame>Baseline = 07:00 to 19:00; Intervention period = 01:00 to 11:00</time_frame>
        <population>Participants in good general health who had CSF collected every 2 hours for 36 hours while undergoing with sleep deprivation, sleep induction with drug, or control conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Sleep Induction</title>
            <description>6.5-7.5 grams of sodium oxybate
Sodium Oxybate: Sodium oxybate h.s.</description>
          </group>
          <group group_id="O2">
            <title>Sleep Deprivation</title>
            <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods
Sleep deprivation: 36hr sleep deprivation</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Increase From Mean Baseline (07:00 to 19:00) of Cerebrospinal Fluid (CSF) Amyloid Beta During Sleep Induction and Sleep Deprivation Between 01:00 and 11:00 From Baseline</title>
          <description>Overnight (01:00 to 11:00) differences in CSF amyloid beta from baseline (07:00 to 19:00) between 1) sleep-deprived and control participants and 2) sleep-induced and control participants.</description>
          <population>Participants in good general health who had CSF collected every 2 hours for 36 hours while undergoing with sleep deprivation, sleep induction with drug, or control conditions.</population>
          <units>percent increase from mean baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="5.7"/>
                    <measurement group_id="O2" value="123" spread="6.6"/>
                    <measurement group_id="O3" value="106" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed linear modeling of change in overnight amyloid beta concentrations from waking baseline between 01:00 and 11:00. Data provided for amyloid beta-40.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed linear models</non_inferiority_desc>
            <p_value>0.07</p_value>
            <p_value_desc>Bonferroni correction was used for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Mean (standard error), units = %. 17(7.2) increase in overnight amyloid-beta 40 concentrations over waking baseline between the sleep deprivation group and controls.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed linear modeling of change in overnight amyloid beta concentrations from waking baseline between 01:00 and 11:00. Data provided for amyloid beta-40.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed linear models</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>Bonferroni correction was used for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Mean= 7%, standard error = 7.6%. 7% increase in overnight amyloid beta 40 concentrations over the waking baseline between the sleep induction group and control group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the start of the participant confinement visits to the Clinical Research Unit when the lumbar catheter was placed and cerebrospinal fluid collected. Adverse event recording continued through a 48 hour telephone follow-up period. Total reporting period was 6 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sleep Induction</title>
          <description>6.5-7.5 grams of sodium oxybate
Sodium Oxybate: Sodium oxybate h.s.</description>
        </group>
        <group group_id="E2">
          <title>Sleep Deprivation</title>
          <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods
Sleep deprivation: 36hr sleep deprivation</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope/syncope with lumbar catheter placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back/neck pain</sub_title>
                <description>Back/neck pain requiring acetaminophen</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache requiring blood patch</sub_title>
                <description>Headache requiring blood patch after removal of the lumbar catheter.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leg tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brendan Lucey</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-4342</phone>
      <email>luceyb@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

